Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

By Haidong Dong, S. Strome, D. Salomao, H. Tamura, F. Hirano, D. Flies, P. Roche, Jun Lu, G. Zhu, K. Tamada and 3 more. Nature Medicine, 2002

2,501 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/6678488400fd2628c46024900ed7198c11364cf1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

PD-1 and its ligands in tolerance and immunity. (2008, result): “Studies in animal models demonstrate that PD-L1 on tumors inhibits T cell activation and lysis of tumor cells and in some cases leads to increased tumor-specific T cell death (123, 136).”
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies (2020, background): “Inhibition of mechanistic target of rapamycin (mTOR), a downstream molecule of PI(3)K–AKT signals, induces expansion 100 a”
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells (2004, background): “Recent evidence suggests that blockade of PD1/PD-L1 interactions might augment antitumor T-cell responses (21, 22), although the phase of T-cell activation regulated by PD-1 is not clear, and a comparison with other inhibitory receptors, such as CTLA-4, has not been explored.”
Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 (2002, background): “(18) recently reported that B7-H1 expressed on tumor cells promoted T cell apoptosis.”
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. (2016, background): “Transcription of PD-L1 can be induced by many cytokines, of which IFN-γ is the most potent (7).”
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (2010, background): “Third, PD-L1 is expressed at high levels in several different cancers (Latchman et al., 2001; Dong et al., 2002; Brown et al., 2003), and high expression of PD-L1 on tumors is strongly associated with poor prognosis (Thompson et al., 2006).”
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (2017, background): “Results PARPi enhances PD-L1 expression in vitro and in vivo Elevated PD-L1 expression in cancer cells has been shown to enhance PD-L1/PD-1 axis–mediated anticancer immunosuppression (11, 16).”
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer (2013, neutral): “Am J Clin Pathol 132(2):202–210, quiz 307.”